Trial · NCT02875132
Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
NCT02875132, Phase 2, Completed, Chinese University of Hong Kong; results first posted 2025-04-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma. Trials, record NCT02875132. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02875132
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
- NCT number
- NCT02875132
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 9 participants, actual
- Lead sponsor
- Chinese University of Hong Kong
- Conditions
- Acral Lentiginous Melanoma
- Interventions
- pembrolizumab
- First posted
- 2016-08-23
- Last updated
- 2025-04-18
- Results first posted
- 2025-04-18
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (ORR) | 2 years | Overall Response Rate (ORR) is defined as rate of complete response (CR) and partial response (PR) as per RECIST 1.1 in biological treatment-naïve patients with acral lentiginous melanoma treated with pembrolizumab |
| Secondary | Response Duration | 2 years | |
| Secondary | Clinical Benefit Rate (CBR) | 2 years | To determine the Clinical Benefit Rate (CBR) of pembrolizumab treatment naïve acral lentiginous melanoma patients as defined by rate of CR + PR and stable disease (SD) of \>/= 6 months |
| Secondary | Progression-free Survival (PFS) | 3 years | |
| Secondary | Overall Survival (OS) | 3 years | |
| Secondary | Response Assessment as Per the Immune-related Response Criteria (irRC) | 2 years | |
| Secondary | Number of Participants With Adverse Events | 2 years |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Response Rate (ORR) | 2 years | participants | NUMBER | |
| SECONDARY | Response Duration | 2 years | months | NUMBER | |
| SECONDARY | Clinical Benefit Rate (CBR) | 2 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Progression-free Survival (PFS) | 3 years | months | MEDIAN | |
| SECONDARY | Overall Survival (OS) | 3 years | months | MEDIAN | |
| SECONDARY | Response Assessment as Per the Immune-related Response Criteria (irRC) | 2 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Adverse Events | 2 years | participants | NUMBER |
Source ClinicalTrials.gov
Results by group7
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) | Pembrolizumab | 1 | 95% Confidence Interval 0 to 31.6 | participants | |
| Response Duration | Pembrolizumab | 19 | months | ||
| Clinical Benefit Rate (CBR) | Pembrolizumab | 4 | Participants | ||
| Progression-free Survival (PFS) | Pembrolizumab | 3.4 | 95% Confidence Interval 1.4 to 21.3 | months | |
| Overall Survival (OS) | Pembrolizumab | 7.6 | 95% Confidence Interval 2 to 34.3 | months | |
| Response Assessment as Per the Immune-related Response Criteria (irRC) | Pembrolizumab | 0 | Participants | ||
| Number of Participants With Adverse Events | Pembrolizumab | 2 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pembrolizumab | 9 | |
| Overall Study | COMPLETED | Pembrolizumab | 9 | |
| Overall Study | NOT COMPLETED | Pembrolizumab | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness | General disorders | Pembrolizumab | 1 | 9 | 1 |
| other | Pleural effusion | Respiratory, thoracic and mediastinal disorders | Pembrolizumab | 1 | 9 | 1 |
| serious | Cough | Respiratory, thoracic and mediastinal disorders | Pembrolizumab | 1 | 9 | 1 |
| serious | Dizziness | Respiratory, thoracic and mediastinal disorders | Pembrolizumab | 1 | 9 | 1 |
| serious | Malaise | Nervous system disorders | Pembrolizumab | 1 | 9 | 1 |
| serious | Pleural effusion | Respiratory, thoracic and mediastinal disorders | Pembrolizumab | 1 | 9 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pembrolizumab | 4 | 9 |
| Total, other adverse events | Pembrolizumab | 2 | 9 |
| Total, serious adverse events | Pembrolizumab | 4 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02875132
GET https://conductscience.org/api/trials/v1/NCT02875132/registered